B Erikstein
Overview
Explore the profile of B Erikstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pust S, Klokk T, Musa N, Jenstad M, Risberg B, Erikstein B, et al.
Oncogene
. 2012 Aug;
32(29):3443-51.
PMID: 22869152
Amplification and overexpression of the receptor tyrosine kinase ErbB2 occur in up to 30% of human breast cancers, and high ErbB2 levels are correlated with poor prognosis for breast cancer...
2.
Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, et al.
Ann Oncol
. 2007 Feb;
18(4):694-700.
PMID: 17301072
Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients And Methods: Five hundred and twenty-five women below the age of 60 years...
3.
Soreide J, Varhaug J, Fjosne H, Erikstein B, Jacobsen A, Skovlund E, et al.
Eur J Surg Oncol
. 2002 Sep;
28(5):505-10.
PMID: 12217302
Aims: To evaluate possible differences in effect on time to recurrence and overall survival in node positive pre-menopausal breast cancer patients (age < or = 50 years) receiving LHRH analogue...
4.
Howell A, Robertson J, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg U, et al.
J Clin Oncol
. 2002 Aug;
20(16):3396-403.
PMID: 12177099
Purpose: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Patients And Methods: Patients...
5.
Lonning P, Kragh L, Erikstein B, Hagen A, Risberg T, Schlichting E, et al.
Clin Cancer Res
. 2002 Mar;
7(12 Suppl):4423s-4428s; discussion 4411s-4412s.
PMID: 11916235
Although SERMs are currently being evaluated and are approved for breast cancer prevention in several countries, aromatase inhibitors and inactivators may represent interesting options in this setting. The encouraging results...
6.
Hall K, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer H, et al.
Breast Cancer Res Treat
. 2001 Sep;
67(3):235-44.
PMID: 11561769
By using N-terminal proatrial natriuretic peptide (proANP) in serum as a marker of cardiac function, we compared the cardiac side effects of two intensive adjuvant treatment regimens for breast cancer....
7.
Kristensen V, Kure E, Erikstein B, Harada N
Mutat Res
. 2001 Sep;
482(1-2):77-82.
PMID: 11535251
Environmental chemicals with estrogenic activities have been suggested to be able to interact with the endocrine system. Endogenous estrogen is synthesized in the ovarian theca cells of premenopausal women or...
8.
Norum L, Erikstein B, Nustad K
Tumour Biol
. 2001 Jun;
22(4):223-8.
PMID: 11399947
The serum tumor markers CA 125, MUC1 and CEA were measured in 221 breast cancer patients over a period of 2 years. Patients examined on at least three occasions were...
9.
Laake K, Vu P, Andersen T, Erikstein B, Karesen R, Lonning P, et al.
Br J Cancer
. 2000 Dec;
83(12):1650-3.
PMID: 11104561
483 Norwegian breast cancer patients were screened for six different ataxia telangiectasia mutated (ATM) mutations previously found to account for 83% of the disease alleles in Norwegian ataxia telangiectasia (AT)...
10.
Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al.
Lancet
. 2000 Oct;
356(9239):1384-91.
PMID: 11052580
Background: Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We...